- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a summary of Glenmark Pharmaceuticals Limited's Q1 FY26 performance:
**1. Financial Highlights:**
Consolidated revenue hit ₹3,264.4 Cr (+0.6% YoY) for Q1 FY26. EBITDA reached ₹580.5 Cr (17.8% margin), with adjusted PAT at ₹312.9 Cr (9.6% margin). India business grew 3.7% to ₹1,239.9 Cr, while North America saw an 8.9% QoQ boost, hitting ₹778.0 Cr.
**2. Strategic Initiatives & Growth Drivers:**
Glenmark is pushing its strategy to drive growth via branded, specialty, and innovative products. New oncology drugs TEVIMBRA® and BRUKINSA® launched in India. Europe aims for double-digit growth in FY26, alongside constant currency double-digit growth expected from Emerging Markets.
**3. Business Developments:**
North America launched 3 products, including generic Adderall®, with 52 ANDAs pending. Global brand RYALTRIS® is now in over 45 markets, showing robust performance. WINLEVI® debuted in the UK, expanding its European reach. Crucially, IGI (Glenmark's innovation arm) partnered with AbbVie for ISB 2001, a novel oncology asset, retaining commercial rights for Emerging Markets.
**4. Market Position & Competitive Advantage:**
India business outperformed the overall pharma market. Consumer Care brands like Candid Powder maintain strong leadership. The AbbVie partnership validates IGI's multi-specific platform technology, strengthening Glenmark's oncology franchise and innovation edge.
**5. Investor Implications:**
These updates signal positive growth potential, especially with new product launches and the strategic AbbVie collaboration. Continued execution on branded and innovative portfolios will be key for long-term value creation.